Updated on 10 July 2012
The study included patients with zero to two previous chemotherapies for advanced disease. Patients were randomized at a ratio of 1:1 to receive treatment with Halaven or capecitabine in accordance with their HER2/neu status and geographic region.
Patients received either Halaven 1.4mg/m2 (administered intravenously over two to five minutes on days one and eight, every 21 days) or capecitabine 2.5g/m2/day (administered orally twice daily in two equal doses on days one-to-14, every 21 days). Adverse events observed in the trial were consistent with the known safety profile of Halaven found in the full prescribing information.
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
